Clinical Cancer Research · 2019 · 46 citations · 28 references
MedicineOncologyPharmacologyBreast OncologyMolecular OncologyOncology PharmacotherapyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerMetabolic ReprogrammingMitochondrial MetabolismMitochondrial PhysiologyEnzyme HistochemistryHer2-positive Breast Cancer TherapyMetabolic TherapiesMitochondrial Respiration InhibitionMitochondrial Respiration SuppressionMitochondrial TargetsTumor Vascular NormalizationVascular Correction
PURPOSE: We previously demonstrated that mitochondrial inhibitors' efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation achievable by inducing vascular normalization/hypoxia correction with antiangiogenics. Vascular normalization can be tracked with 2[18F]fluoro-2-deoxy-d-glucose (FDG)-PET. We tested the efficacy of the mitochondrial inhibitor ME-344 or placebo added to bevacizumab in early breast cancer. PATIENTS AND METHODS: F-fluorodeoxyglucose (FDG)-PET (day 1) and received a single dose of bevacizumab (15 mg/kg), followed by a second FDG-PET (day 8). Patients were then randomized (1:1) to Arm A (ME-344 10 mg/kg intravenous on days 8, 15, and 21) or Arm B (placebo). Tumors were biopsied on days 0 and 29. Succinate dehydrogenase enzyme histochemistry (SDH-EHC), confocal microscopy of vessel architecture, and HIF1α staining were performed in pre- and posttreatment biopsies to assess the pharmacodynamics, vessel normalization, and tissue re-oxygenation by bevacizumab, respectively. RESULTS: = 42 patients). FDG-PET predicted vascular normalization in about one-third of the patients in each arm, which was confirmed using confocal microscopy and HIF1α staining. In the subgroup with vascular normalization, ME-344 induced a Ki67 decrease of 33.4% (placebo: 11.8 increase). SDH-EHC suggested on-target effects of ME-344. CONCLUSIONS: ME-344 has significant biological antitumor activity in HER2-negative breast cancer, particularly after induction of vascular normalization and tissue reoxygenation with bevacizumab.
28
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text
Medicine, Hematology, Oncology +17
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Andrea Viale, Piergiorgio Pettazzoni, Costas A. Lyssiotis et al. · Nature · 2014 · 1.2K citations · Full text
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
William W. Wheaton, Samuel E. Weinberg, Robert B. Hamanaka et al. · eLife · 2014 · 1.1K citations · Full text
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 951 citations · Full text
Medicine, Cancer Biology, Oncology +14